Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm

Annals of Oncology

Volumn 28, Issue 3, 2017, Pages 673-675

  Haddox, C L ^a   Shenoy, N ^a   Shah, K K ^a   Kao, J C ^a   Jain, S ^a   Halfdanarson, T R ^a   Wijdicks, E F ^a   Goetz, M P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATINE KINASE; PEMBROLIZUMAB; PREDNISONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; CASE REPORT; DYSARTHRIA; DYSPHAGIA; ELECTROMYOGRAPHY; FACIAL NERVE PARALYSIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOCYTE COUNT; LIMB WEAKNESS; MALE; METASTATIC MELANOMA; MYALGIA; MYOCARDITIS; MYOPATHY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PTOSIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; CHEMICALLY INDUCED; DIAPHRAGM; DRUG EFFECTS; MELANOMA; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DIAPHRAGM; HUMANS; MALE; MELANOMA; MYOSITIS; RESPIRATORY INSUFFICIENCY;

EID: 85018320215     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw655     Document Type: Letter

References (7)

1. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
2. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
3. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
4. Sul J, Blumenthal GM, Jiang X et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21: 643-650.
5. Chow LQ, Haddad R, Gupta S et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016 Sep 19 [Epub ahead of print]; pii:JCO681473.
6. Zimmer SMG L, Hofmann L, Loquai C et al. Neurological, respiratory, musculoskeletal, cardiac andocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-225.
7. Vallet HGA, Weiss N, Vanhaecke C et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 2016; 27: 1352-1353.